Antidiabetics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022 - 2027

Report Code: HCR 0155 Report Format: PDF + Excel

Antidiabetics Market Overview

Antidiabetics Market size is estimated to reach $136 billion by 2027, growing at a CAGR of 9.8% during the forecast period 2022-2027. The anti-diabetics market involves drugs, which are utilized for the treatment of diabetes mellitus and are also termed oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has developed enormously in current years with the increasing pervasiveness of diabetes mellitus. The gastric inhibitory polypeptide (GIP) or gastro inhibitory peptide, also termed the glucose-dependent insulinotropic peptide, is an inhibiting hormone of the secretin family of hormones. While it is not a strong inhibitor of gastric acid secretion, its principal role is to encourage insulin secretion. Alpha-glucosidase inhibitor (AGI) is an oral anti-diabetic medication utilized for diabetes mellitus type 2 that performs by averting the digestion of carbohydrates (like starch and table sugar). Oral antihyperglycemic therapy for type 2 diabetes mellitus has been extensively investigated. It is vital to mention that the orally administered antihyperglycemic agents (OHAs) utilized in the treatment of diabetes have also been reviewed in the context of prevention. Glycated Hemoglobin Test is a test that is occasionally utilized to diagnose diabetes mellitus but is more typically utilized to observe how the blood sugar levels have been in patients already diagnosed with diabetes. The glycated hemoglobin test is based on the quantity of sugar (glucose) tied to the hemoglobin within the red blood cells.

The development of erratic dietary habits and obesity are set to drive the Antidiabetics Market. The accelerated comeback of DPP-4 inhibitors like Januvia, Nesina, and Onglyza owing to their once-every-day dosage procedures and safety profiles and the application of alpha-glucosidase inhibitor is set to propel the growth of the Antidiabetics Market during the forecast period 2022-2027. This represents the Antidiabetics Industry Outlook.

Report Coverage

The report: Antidiabetics Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Antidiabetics Market.

By Product Type: Insulin, Biguanides, Thiazolidinediones, GLP-Agonists, Sulphonylureas, DPP-4 Inhibitors, SGLT-2, Alpha-Glucosidase Inhibitors, Meglitinides.

By Application: Type I Diabetes, Type II Diabetes.

By Geography: North America (the U.S, Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

  • Geographically, North America Antidiabetics Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the great market infiltration of insulin and additional anti-diabetic medications like alpha-glucosidase inhibitors in the North American region.
  • Antidiabetics Market growth is being driven by the increasing predominance of diabetes worldwide which may involve the application of alpha-glucosidase inhibitors and the growing count of programs commenced by different health organizations associated with health awareness pertaining to diabetes. However, the side-effects of anti-diabetic drugs like continued application of sulphonylureas on patients are inclined to bring about hypoglycemia and gentle weight gain and this is one of the major factors hampering the growth of the Antidiabetics Market. 
  • Antidiabetics Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Antidiabetics Market report

Antidiabetics Market: Market Share (%) by Region, 2021

For More Details on This Report - Request for Sample

Antidiabetics Market Segment Analysis – By Product Type:

The Antidiabetics Market based on product type can be further segmented into Insulin, Biguanides, Thiazolidinediones, GLP-Agonists, Sulphonylureas, DPP-4 Inhibitors, SGLT-2, Alpha-Glucosidase Inhibitors, and Meglitinides. The Insulin Segment held the largest market share in 2021. This growth is owing to the soaring application of insulin in conjunction with efficient therapeutic characteristics related to the product. The alpha-glucosidase inhibitor is utilized to treat Type II Diabetes. The introduction of novel products in conjunction with the forthcoming commercialization of products presently in the pipeline is further propelling the growth of the Insulin segment.

Furthermore, the Biguanides segment is estimated to grow with the fastest CAGR of 10.4% during the forecast period 2022-2027 owing to the advantages of Biguanides like minimization of the risk of heart disease in addition to reduced blood sugar apart from  Alpha-glucosidase inhibitor being utilized to treat Type II Diabetes.  

Antidiabetics Market Segment Analysis – By Application:

The Antidiabetics Market based on the application can be further segmented into Type I Diabetes and Type II Diabetes. The Type II Diabetes Segment held the largest market share in 2021. This growth is owing to the soaring count of diabetic patients with Type II Diabetes worldwide. The alpha-glucosidase inhibitor is used to treat Type II Diabetes. People above the age of 45 are at greater risk of Type II Diabetes. The increasing predominance of obesity and family history with diabetes are further propelling the growth of this segment.

Furthermore, the Type II Diabetes segment is estimated to grow with the fastest CAGR of 10.5% during the forecast period 2022-2027 owing to the predominant sedentary lifestyle in contemporary times requiring the application of Alpha-glucosidase inhibitor with other probable risk factors being prediabetes, gestational diabetes, and Polycystic ovarian syndrome.

Antidiabetics Market Segment Analysis – By Geography:

The Antidiabetics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Antidiabetics Market) held the largest share with 36% of the overall market in 2021. The growth of this region is owing to the great progressive healthcare infrastructure in the region. The surging application of Alpha-Glucosidase Inhibitor to treat Type 2 Diabetes is further driving the growth of the Antidiabetics market in this region. The increasing count of pediatric diabetes patients in conjunction with the surging requirement for management of diabetes amidst COVID-19 patients is further propelling the growth of the Antidiabetics market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the rising predominance of Type 1 and Type 2 Diabetes and the accelerated enhancement of healthcare spending in the Asia-Pacific region. The existence of countries like India which is struggling with diabetes involving the application of antidiabetics like Alpha-glucosidase inhibitor is further fueling the progress of the Antidiabetics market in the Asia-Pacific region.

Antidiabetics Market Drivers

  • Surging Applications Of Alpha-Glucosidase Inhibitor Are Projected To Drive The Growth Of Antidiabetics Market:

Alpha-glucosidase inhibitor (AGI) is a class of medications that are utilized in the treatment of type 2 diabetes mellitus, just by itself or integrated with additional antidiabetic medications. They may also be utilized in patients with damaged glucose tolerance and defer the happening of type 2 diabetes mellitus in these patients. They are specifically convenient for patients who are at risk of hypoglycemia or lactic acidosis. The U.S. Food And Drug Administration (FDA) endorses AGIs for the treatment of type 2 diabetes mellitus. They have demonstrated certain advantages in type 1 diabetes mellitus and gestational diabetes mellitus but are not FDA-endorsed for these indications. AGIs are specifically convenient for minimizing postprandial hyperglycemia. They reasonably reduce glycosylated hemoglobin levels and also minimize postprandial insulin concentration. The surging applications of Alpha-Glucosidase Inhibitor are therefore fuelling the growth of the Antidiabetics Market during the forecast period 2022-2027.

  • Increasing Predominance Of Diabetes Is Expected To Boost The Demand Of Antidiabetics Market:

As per World Health Organization (WHO), the count of people with diabetes increased from 108 million in 1980 to 422 million in 2014, and in 2019, diabetes was the ninth chief cause of demise with an approximate 1.5 million demises directly brought about by diabetes. Further WHO updates indicate that Type 2 diabetes (previously termed non-insulin-dependent, or adult-onset) is brought about by the inefficient application of the body of insulin, and over 95% of people with diabetes have type 2 diabetes. This kind of diabetes is mostly brought about by excessive body weight and physical inaction. Antidiabetics prescribed for Type 2 diabetes include Metformin, Sulphonylureas, Glitazones, Glinides, and Alpha-Glucosidase Inhibitor. The increasing pervasiveness of diabetes is thus driving the growth of the Antidiabetics Market during the forecast period 2022-2027.

Antidiabetics Market Challenges

  • Concurrent Application Of Antidiabetic Herbs And Pharmaceutical Medications Is Hampering The Growth Of The Antidiabetics Market:

The worldwide application of complementary and alternative medicine (CAM) for the handling of ailments like diabetes has quickly heightened over the last ten years. Research indicates that the majority of people who utilize CAM therapies do so in conjunction with, instead of, traditional medication. A massive count of medicinal plants is thought to have anti-diabetic characteristics and have been used to handle diabetes. However, the simultaneous application of antidiabetic herbs and pharmaceutical medications has increased safety concerns. Unlike pharmaceutical medications, where the constituents are well defined and featured, herbal medication includes numerous bioactive constituents for which there is a dearth of comprehension of how these constituents communicate with each other and with pharmaceutical medications when taken in integration. This issue is hampering the growth of the Antidiabetics Market.

Antidiabetics Market - Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antidiabetics Market. Key companies of this market are:

  1. Novo Nordisk A/S
  2. Eli Lilly and Company
  3. Sanofi S.A.
  4. Merck & Co. Inc
  5. Boehringer Ingelheim
  6. AstraZeneca PLC
  7. Johnson & Johnson
  8. Merck KGaA
  9. Bayer
  10. Takeda Pharmaceutical Company Limited

Recent Developments

  • In June 2021, Sanofi introduced a €3 million Planet Mobilization fund to back employee ideas and projects that will further add to a healthier atmosphere. This year, three Sanofi teams will have their projects financed. For numerous years, Sanofi has been establishing an environmental roadmap worldwide, Planet Mobilization, which is entrenched in Sanofi’s long-term strategy.
  • In May 2021, it was reported that Novo Nordisk was to introduce GLP-1 injectable diabetes medication in tablet form by February. Oral medication is being viewed as a progressive technology that could alter the approach and adoption of the medication for patients in India, which presently has the problematic distinction of being the diabetes capital of the world. It is publicized as an oral medication that pledges to not just support diabetes patients handling the disease but also perhaps provide additional advantages like weight minimization and minimized cardiac hazard.
  • In February 2020, Novo Nordisk declared that ESPEROCT® [antihemophilic factor (recombinant), glycopegylated-exei] is currently accessible in the U.S. for the treatment of adults and children with hemophilia A. ESPEROCT® is a recombinant extended half-life factor VIII replacement therapy utilized to avert or minimize the count of bleeding episodes, to treat and curb bleeding, and to handle bleeding at the time of surgery in people with hemophilia A. When utilized by mature grown-ups every four days, ESPEROCT® can support minimization of the frequency of bleeding with fewer frequent dosing.

Related Reports-

Diabetes Care Devices Market – Forecast (2021 - 2026)

Report Code: HCR 0574

Diabetes Therapeutics Market

Report Code: HCR 89201

For more Lifesciences and Healthcare Market reports, please click here

1. Antidiabetics Market Overview
    1.1 Definitions and Scope
2. Antidiabetics Market - Executive Summary
3. Antidiabetics Market– Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Antidiabetics Market– Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Antidiabetics Market– Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Antidiabetics Market- Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Antidiabetics Market– By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Antidiabetics Market - By Product Type (Market Size –$Million/$Billion) 
    8.1 Insulin
    8.2 Biguanides
    8.3 Thiazolodinediones
    8.4 GLP-Agonists
    8.5 Sulphonylureas
    8.6 DPP-4 Inhibitors
    8.7 SGLT-2
    8.8 Alpha-Glucosidase Inhibitors
    8.9 Meglitinides
9. Antidiabetics Market – By Application (Market Size –$Million/$Billion) 
    9.1 Type I Diabetes
    9.2 Type II Diabetes
10. Antidiabetics Market- By Geography (Market Size -$Million/Billion)
    10.1 North America
        10.1.1 U.S
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 Germany
        10.2.2 France
        10.2.3 UK
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 Japan
        10.3.3 South Korea
        10.3.4 India
        10.3.5 Australia & New Zealand
        10.3.6 Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Chile
        10.4.4 Colombia
        10.4.5 Rest of South America
    10.5 Rest Of The World
    10.5.1 Middle East
    10.5.2 Africa
11. Antidiabetics Market- Market Entropy
    11.1 New product launches
    11.2 M&A's, collaborations, JVs and partnerships
12. Antidiabetics Market– Industry Competition Landscape (Premium)
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key Companies
        12.1.3 Market Share by Countries – Key Companies
    12.2 Competition Matrix
    12.3 Best Practices for Companies
13. Antidiabetics Market– Key Company List by Country Premium (Premium)
14. Antidiabetics Market- Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"
List of Tables:

Table 1: Antidiabetics Market Analysis Overview 2021-2026
Table 2: Antidiabetics Market Analysis Leader Analysis 2018-2019 (US$)
Table 3: Antidiabetics Market Analysis Product Analysis 2018-2019 (US$)
Table 4: Antidiabetics Market Analysis End User Analysis 2018-2019 (US$)
Table 5: Antidiabetics Market Analysis Patent Analysis 2013-2018* (US$)
Table 6: Antidiabetics Market Analysis Financial Analysis 2018-2019 (US$)
Table 7: Antidiabetics Market Analysis Driver Analysis 2018-2019 (US$)
Table 8: Antidiabetics Market Analysis Challenges Analysis 2018-2019 (US$)
Table 9: Antidiabetics Market Analysis Constraint Analysis 2018-2019 (US$)
Table 10: Antidiabetics Market Analysis Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Antidiabetics Market Analysis Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Antidiabetics Market Analysis Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Antidiabetics Market Analysis Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Antidiabetics Market Analysis Degree of Competition Analysis 2018-2019 (US$)
Table 15: Antidiabetics Market Analysis Value Chain Analysis 2018-2019 (US$)
Table 16: Antidiabetics Market Analysis Pricing Analysis 2021-2026 (US$)
Table 17: Antidiabetics Market Analysis Opportunities Analysis 2021-2026 (US$)
Table 18: Antidiabetics Market Analysis Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Antidiabetics Market Analysis Supplier Analysis 2018-2019 (US$)
Table 20: Antidiabetics Market Analysis Distributor Analysis 2018-2019 (US$)
Table 21: Antidiabetics Market Analysis Trend Analysis 2018-2019 (US$)
Table 22: Antidiabetics Market Analysis Size 2018 (US$)
Table 23: Antidiabetics Market Analysis Forecast Analysis 2021-2026 (US$)
Table 24: Antidiabetics Market Analysis Sales Forecast Analysis 2021-2026 (Units)
Table 25: Antidiabetics Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 26: Antidiabetics Market Analysis By Drugs Type, Revenue & Volume,By Insulin, 2021-2026 ($)
Table 27: Antidiabetics Market Analysis By Drugs Type, Revenue & Volume,By Rapid acting, 2021-2026 ($)
Table 28: Antidiabetics Market Analysis By Drugs Type, Revenue & Volume,By Long acting, 2021-2026 ($)
Table 29: Antidiabetics Market AnalysisBy Drugs Type, Revenue & Volume,By Sulphonylureas, 2021-2026 ($)
Table 30: Antidiabetics Market AnalysisBy Drugs Type, Revenue & Volume,By Biguanides, 2021-2026 ($)
Table 31: North America Antidiabetics Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 32: South america Antidiabetics Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 33: Europe Antidiabetics Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 34: APAC  Antidiabetics Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 35: Middle East & Africa Antidiabetics Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 36: Russia Antidiabetics Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 37: Israel Antidiabetics Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 38: Top Companies 2018 (US$)Antidiabetics Market Analysis, Revenue & Volume
Table 39: Product Launch 2018-2019 Antidiabetics Market Analysis, Revenue & Volume
Table 40: Mergers & Acquistions 2018-2019 Antidiabetics Market Analysis, Revenue & Volume


List of Figures:

Figure 1: Overview of Antidiabetics Market Analysis 2021-2026
Figure 2: Market Share Analysis for Antidiabetics Market Analysis 2018 (US$)
Figure 3: Product Comparison in Antidiabetics Market Analysis 2018-2019 (US$)
Figure 4: End User Profile for Antidiabetics Market Analysis 2018-2019 (US$)
Figure 5: Patent Application and Grant in Antidiabetics Market Analysis 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Antidiabetics Market Analysis 2018-2019 (US$)
Figure 7: Market Entry Strategy in Antidiabetics Market Analysis 2018-2019
Figure 8: Ecosystem Analysis in Antidiabetics Market Analysis 2018
Figure 9: Average Selling Price in Antidiabetics Market Analysis 2021-2026
Figure 10: Top Opportunites in Antidiabetics Market Analysis 2018-2019
Figure 11: Market Life Cycle Analysis in Antidiabetics Market Analysis
Figure 12: Global By Drugs Type Antidiabetics Market Analysis Revenue, 2021-2026 ($)
Figure 13: Global Antidiabetics Market Analysis - By Geography
Figure 14: Global Antidiabetics Market Analysis Value & Volume, By Geography, 2021-2026 ($) 
Figure 15: Global Antidiabetics Market Analysis CAGR, By Geography, 2021-2026 (%)
Figure 16: North America Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 17: US Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 18: US GDP and Population, 2018-2019 ($)
Figure 19: US GDP – Composition of 2018, By Sector of Origin
Figure 20: US Export and Import Value & Volume, 2018-2019 ($)
Figure 21: Canada Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 22: Canada GDP and Population, 2018-2019 ($)
Figure 23: Canada GDP – Composition of 2018, By Sector of Origin
Figure 24: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Mexico Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 26: Mexico GDP and Population, 2018-2019 ($)
Figure 27: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29: South America Antidiabetics Market Analysis South America 3D Printing  Market Value & Volume, 2021-2026 ($)
Figure 30: Brazil Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 31: Brazil GDP and Population, 2018-2019 ($)
Figure 32: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34: Venezuela Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 35: Venezuela GDP and Population, 2018-2019 ($)
Figure 36: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Argentina Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 39: Argentina GDP and Population, 2018-2019 ($)
Figure 40: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Ecuador Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 43: Ecuador GDP and Population, 2018-2019 ($)
Figure 44: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Peru Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 47: Peru GDP and Population, 2018-2019 ($)
Figure 48: Peru GDP – Composition of 2018, By Sector of Origin
Figure 49: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Colombia Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 51: Colombia GDP and Population, 2018-2019 ($)
Figure 52: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Costa Rica Antidiabetics Market AnalysisCosta Rica 3D Printing  Market Value & Volume, 2021-2026 ($)
Figure 55: Costa Rica GDP and Population, 2018-2019 ($)
Figure 56: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Europe Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 59: U.K Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 60: U.K GDP and Population, 2018-2019 ($)
Figure 61: U.K GDP – Composition of 2018, By Sector of Origin
Figure 62: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63: Germany Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 64: Germany GDP and Population, 2018-2019 ($)
Figure 65: Germany GDP – Composition of 2018, By Sector of Origin
Figure 66: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Italy Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 68: Italy GDP and Population, 2018-2019 ($)
Figure 69: Italy GDP – Composition of 2018, By Sector of Origin
Figure 70: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71: France Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 72: France GDP and Population, 2018-2019 ($)
Figure 73: France GDP – Composition of 2018, By Sector of Origin
Figure 74: France Export and Import Value & Volume, 2018-2019 ($)
Figure 75: Netherlands Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 76: Netherlands GDP and Population, 2018-2019 ($)
Figure 77: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Belgium Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 80: Belgium GDP and Population, 2018-2019 ($)
Figure 81: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Spain Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 84: Spain GDP and Population, 2018-2019 ($)
Figure 85: Spain GDP – Composition of 2018, By Sector of Origin
Figure 86: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Denmark Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 88: Denmark GDP and Population, 2018-2019 ($)
Figure 89: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91: APAC Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 92: China Antidiabetics Market AnalysisValue & Volume, 2021-2026
Figure 93: China GDP and Population, 2018-2019 ($)
Figure 94: China GDP – Composition of 2018, By Sector of Origin
Figure 95: China Export and Import Value & Volume, 2018-2019 ($)Antidiabetics Market AnalysisChina Export and Import Value & Volume, 2018-2019 ($)
Figure 96: Australia Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 97: Australia GDP and Population, 2018-2019 ($)
Figure 98: Australia GDP – Composition of 2018, By Sector of Origin
Figure 99: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100: South Korea Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 101: South Korea GDP and Population, 2018-2019 ($)
Figure 102: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104: India Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 105: India GDP and Population, 2018-2019 ($)
Figure 106: India GDP – Composition of 2018, By Sector of Origin
Figure 107: India Export and Import Value & Volume, 2018-2019 ($)
Figure 108: Taiwan Antidiabetics Market AnalysisTaiwan 3D Printing  Market Value & Volume, 2021-2026 ($)
Figure 109: Taiwan GDP and Population, 2018-2019 ($)
Figure 110: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Malaysia Antidiabetics Market AnalysisMalaysia 3D Printing  Market Value & Volume, 2021-2026 ($)
Figure 113: Malaysia GDP and Population, 2018-2019 ($)
Figure 114: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Hong Kong Antidiabetics Market AnalysisHong Kong 3D Printing  Market Value & Volume, 2021-2026 ($)
Figure 117: Hong Kong GDP and Population, 2018-2019 ($)
Figure 118: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Middle East & Africa Antidiabetics Market AnalysisMiddle East & Africa 3D Printing  Market Value & Volume, 2021-2026 ($)
Figure 121: Russia Antidiabetics Market AnalysisRussia 3D Printing  Market Value & Volume, 2021-2026 ($)
Figure 122: Russia GDP and Population, 2018-2019 ($)
Figure 123: Russia GDP – Composition of 2018, By Sector of Origin
Figure 124: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125: Israel Antidiabetics Market Analysis Value & Volume, 2021-2026 ($)
Figure 126: Israel GDP and Population, 2018-2019 ($)
Figure 127: Israel GDP – Composition of 2018, By Sector of Origin
Figure 128: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129:  Entropy Share, By Strategies, 2018-2019* (%)Antidiabetics Market Analysis
Figure 130:  Developments, 2018-2019*Antidiabetics Market Analysis
Figure 131: Company 1 Antidiabetics Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 132: Company 1 Antidiabetics Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 133: Company 1 Antidiabetics Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 134: Company 2 Antidiabetics Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 2 Antidiabetics Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 2 Antidiabetics Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 137: Company 3Antidiabetics Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 138: Company 3Antidiabetics Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 139: Company 3Antidiabetics Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 140: Company 4 Antidiabetics Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 141: Company 4 Antidiabetics Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 142: Company 4 Antidiabetics Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 143: Company 5 Antidiabetics Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 144: Company 5 Antidiabetics Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 145: Company 5 Antidiabetics Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 146: Company 6 Antidiabetics Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 147: Company 6 Antidiabetics Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 148: Company 6 Antidiabetics Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 149: Company 7 Antidiabetics Market Analysis  Net Revenue, By Years, 2018-2019* ($)
Figure 150: Company 7 Antidiabetics Market Analysis  Net Revenue Share, By Business segments, 2018 (%)
Figure 151: Company 7 Antidiabetics Market Analysis  Net Sales Share, By Geography, 2018 (%)
Figure 152: Company 8 Antidiabetics Market Analysis  Net Revenue, By Years, 2018-2019* ($)
Figure 153: Company 8 Antidiabetics Market Analysis  Net Revenue Share, By Business segments, 2018 (%)
Figure 154: Company 8 Antidiabetics Market Analysis  Net Sales Share, By Geography, 2018 (%)
Figure 155: Company 9 Antidiabetics Market Analysis  Net Revenue, By Years, 2018-2019* ($)
Figure 156: Company 9 Antidiabetics Market Analysis  Net Revenue Share, By Business segments, 2018 (%)
Figure 157: Company 9 Antidiabetics Market Analysis  Net Sales Share, By Geography, 2018 (%)
Figure 158: Company 10 Antidiabetics Market Analysis  Net Revenue, By Years, 2018-2019* ($)
Figure 159: Company 10 Antidiabetics Market Analysis  Net Revenue Share, By Business segments, 2018 (%)
Figure 160: Company 10 Antidiabetics Market Analysis  Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 11 Antidiabetics Market Analysis  Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 11 Antidiabetics Market Analysis  Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 11 Antidiabetics Market Analysis  Net Sales Share, By Geography, 2018 (%)
Figure 164: Company 12 Antidiabetics Market Analysis  Net Revenue, By Years, 2018-2019* ($)
Figure 165: Company 12 Antidiabetics Market Analysis  Net Revenue Share, By Business segments, 2018 (%)
Figure 166: Company 12 Antidiabetics Market Analysis  Net Sales Share, By Geography, 2018 (%)
Figure 167: Company 13Antidiabetics Market Analysis  Net Revenue, By Years, 2018-2019* ($)
Figure 168: Company 13Antidiabetics Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 169: Company 13Antidiabetics Market Analysis  Net Sales Share, By Geography, 2018 (%)
Figure 170: Company 14 Antidiabetics Market Analysis  Net Revenue, By Years, 2018-2019* ($)
Figure 171: Company 14 Antidiabetics Market Analysis  Net Revenue Share, By Business segments, 2018 (%)
Figure 172: Company 14 Antidiabetics Market Analysis  Net Sales Share, By Geography, 2018 (%)
Figure 173: Company 15 Antidiabetics Market Analysis  Net Revenue, By Years, 2018-2019* ($)
Figure 174: Company 15 Antidiabetics Market Analysis  Net Revenue Share, By Business segments, 2018 (%)
Figure 175: Company 15 Antidiabetics Market Analysis  Net Sales Share, By Geography, 2018 (%)